N-(5Z，8Z，11Z，14Z)-5,8,11,14-二十碳四烯-1-基-4-羟基苯甲酰胺 | 251908-92-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: N-(5Z，8Z，11Z，14Z)-5,8,11,14-二十碳四烯-1-基-4-羟基苯甲酰胺
• 英文名称: N-(5Z,8Z,11Z,14Z)-5,8,11,14-eicosatetraen-1-yl-4-hydroxybenzamide
• 英文别名: 4-hydroxy-N-[(5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenyl]benzamide
• CAS: 251908-92-6
• 化学式: C₂₇H₃₉NO₂
• 分子量: 409.6
• InChiKey: XCWBOAHOJHPWLA-DOFZRALJSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.8
• 重原子数：
  30
• 可旋转键数：
  16
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  49.3
• 氢给体数：
  2
• 氢受体数：
  2

文献信息

• Methods of using cannabinoids and/or molecular similars for modulating, waking-up and/or disabling cellular functions involved in causing disease -- reinvigorating metabolism with anandamide, 2-arachidonoylglycerol and similarly acting compounds
  申请人：Postrel Richard

  公开号：US20190000795A1

  公开（公告）日：2019-01-03

  Methods using cannabinoids and/or molecular similars for modulating, waking-up and/or disabling cellular functions involved in causing disease are provided for reinvigorating metabolism, including human metabolism. As humans age stresses they encounter cause their cells to respond opportunistically to counter each stress. Each of these responses involves at least minor shifts or compromises in metabolism. As these metabolic compromises multiply, metabolism continues to deviate from its optimum. Several lipophilic compounds are active in membranes of cells, including the plasma membrane, nuclear membrane, endoplasmic reticulum membrane and mitochondrial membrane. These lipophilic compounds, act with cannabinoid receptors to affect virtually all cell functions. By choosing specific endocannabinoids and/or analogues and targeting them at opportunistically deteriorated portions of metabolism through one of several specific endocannabinoid receptor proteins in a stepwise manner metabolism can be reinvigorated towards its optimal status.
• [EN] THERAPEUTIC RELEASE AGENTS<br/>[FR] AGENTS DE LIBÉRATION THÉRAPEUTIQUES
  申请人：ORGANON NV

  公开号：WO2008100977A2

  公开（公告）日：2008-08-21

  [EN] Pharmacological inhibition of fatty acid amide hydrolase (FAAH) activity leads to increased levels of fatty acid amides. Esters of alkylcarbamic acids are disclosed that are inhibitors of FAAH activity. Compounds disclosed herein inhibit FAAH activity. Described herein are processes for the preparation of esters of alkylcarbamic acid compounds, compositions that include them, and methods of use thereof.
  [FR] L'inhibition pharmacologique de l'activité de l'amide hydrolase d'acides gras (FAAH) entraîne une augmentation des taux d'amides d'acides gras. L'invention concerne des esters d'acides alkylcarbamiques qui constituent des inhibiteurs de l'activité de la FAAH. Les composés décrits inhibent l'activité de la FAAH. L'invention concerne aussi des procédés de préparation d'esters de composés d'acides alkylcarbamiques, des compositions renfermant ceux-ci et des procédés d'utilisation de celles-ci.